Lung Cancer development and mortality in interstitial lung disease with and without connective tissue diseases: a five-year Nationwide population-based study

Choi, Won‐Il; Lee, Dong Yoon; Choi, Hyungi; Lee, Choong Won

doi:10.1186/s12931-019-1094-y

Cited by 19 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence densities of LC in patients with CTD-ILDs were also reported in two previous studies as 0.98 and 1.66 per 100 person-years [14,15]. Thus, the incidence density of LC in CTD-ILD patients in this study was slightly lower than the values in previous reports [14,15]. Moreover, Choi et al reported that the incidence densities of LC in IPF and IIP patients were 3.81 and 1.57 per 100 person-years, respectively, and that the incidence of LC in IPF patients was higher than that in IIP patients based on data from the Korean national database [13].…”

Section: Discussionsupporting

confidence: 70%

“…The incidence rate in this study was comparable with those in previous reports on IPF patients. The incidence densities of LC in patients with CTD-ILDs were also reported in two previous studies as 0.98 and 1.66 per 100 person-years [14,15]. Thus, the incidence density of LC in CTD-ILD patients in this study was slightly lower than the values in previous reports [14,15].…”

Section: Discussionsupporting

confidence: 50%

“…Choi et al reported that the incidence of LC in IPF patients was higher than those in IIP patients and COPD patients [13]. High incidences of LC in patients with CTD-ILDs [14,15] and IIPs [13] have also been reported. The prevalence of LC in chronic HP patients has been reported, but the incidence has not yet [16].…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Cumulative Incidences of Lung Cancer in Various Interstitial Lung Diseases

Suzuki

Sakashita

Akiyama

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Interstitial lung disease (ILD) patients often develop lung cancer. However, previous studies on the incidences of lung cancer in ILD patients focused on specific aetiologies, such as idiopathic pulmonary fibrosis (IPF). The lung cancer incidences in these patients have not been investigated, and thus, we aimed to evaluate them here. Methods ILD patients at our hospital were retrospectively reviewed. The cumulative incidences of lung cancer in patients with various ILDs were estimated with Kaplan-Meier curves and compared between ILD groups using log-rank tests. The association between several variables at initial diagnosis and lung cancer development was assessed with Cox proportional hazards regression analysis to identify predictors. Results In all, 606 ILD patients, including 161 with IPF, 133 with non-IPF idiopathic interstitial pneumonias, 160 with chronic hypersensitivity pneumonitis, 87 with connective tissue disease-related ILDs, 19 with pulmonary sarcoidosis, and 46 with other ILDs, were included. Twenty-eight patients developed lung cancer. The cumulative incidences of lung cancer at 1, 3, and 5 years were: 1.9, 5.7, and 12.3% with IPF, respectively; 0.8, 0.8, and 4.0% in non-IPF idiopathic interstitial pneumonias; 2.0, 4.6, and 11.0% in chronic hypersensitivity pneumonitis; and 1.1, 1.1, and 2.9% in connective tissue disease-related ILDs. IPF patients had a higher incidence of lung cancer than non-IPF idiopathic interstitial pneumonia patients (p = 0.036). A radiological usual interstitial pneumonia pattern, forced vital capacity value, and pack-years were associated with lung cancer development (hazard ratios 2.959, 1.031, 1.011; 95% confidence intervals 1.257–6.963, 1.006–1.057, 1.002–1.020, p = 0.013, 0.017, 0.020, respectively). Conclusions The lung cancer incidence is higher in IPF patients than in non-IPF idiopathic interstitial pneumonia patients and is equally high in patients with chronic hypersensitivity pneumonitis and IPF.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionsupporting

confidence: 50%

See 1 more Smart Citation

Cumulative Incidences of Lung Cancer in Various Interstitial Lung Diseases

Suzuki

Sakashita

Akiyama

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Patients who were less than 60 years old with connective tissue disease-associated ILD (CTD-ILD) were more likely to have concurrent malignancies than CTD-only patients. [ 45 ] However, studies on the association between ILD and malignancy in DM patients have shown that the presence of a malignancy occurs less frequently in the DM-ILD group than in the non-DM-ILD group. [ 2 , 12 , 29 , 34 ] In our cohort, 77.84% of DM patients had ILD.…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies

Shao

Sun

et al. 2020

Medicine

View full text Add to dashboard Cite

Although a strong association between idiopathic inflammatory myositis (IIM) and malignancy has been widely reported, few studies have solely focused on the concurrence of dermatomyositis (DM) and malignancies (DM-malignancy). We conducted a retrospective analysis of 37 DM-malignancy cases among 363 DM patients admitted to our hospital between January 2012 and December 2017. (1) The mean age at DM diagnosis was higher for DM-malignancy patients than for DM-non-malignancy patients [(54.76 ± 9.77) years vs (48.57 ± 12.82) years, t = 2.84, P = .005]. (2) Gynecological malignancies (35.90%/14 cases) were the most common malignancies. Malignancies were diagnosed before DM for 7 DM-malignancy patients. The interval between the DM and malignancy diagnoses for the remaining 32 DM-malignancy patients was less than 6 months for 18 patients (46.15%), less than 1 years for 23 patients (58.9%), and less than 2 years for 29 patients (74.26%). (3) There was no significant difference either in antinuclear antibody or anti-Ro-52 positivity between the 2 groups ( P > .05). (4) Multivariate analysis demonstrated that DM onset age ≥50 years and concurrence with ILD increased the risk of death for DM patients [hazard ratio (HR): 1.62 and 2.72; 95% confidence interval (CI): (1.08–2.43) and (1.47–5.02); P = .02 and 0.001, respectively], and male gender decreased the risk of death [HR 0.66, 95% CI (0.44–0.98), P = .04]. DM-malignancy patients were older than DM-non-malignancy patients. Gynecological malignancies were the most common malignancies among these patients. A DM onset age ≥50 years, female sex and the presence of ILD were independent risk factors for death.

show abstract

“…Non-small cell lung cancer (NSCLC) is a primary class of lung cancer and ~85% of lung cancer cases are classified as NSCLC (3,4). Although great advancements have made in the clinic, the prognosis of NSCLC remains poor and the 5 year survival rate of patients from Europe with NSCLC remained at <15% in 2016, which may be due to the limitations of early detection methods (5)(6)(7). Thus, numerous recent studies have focused on investigating the molecular mechanisms associated with NSCLC progression in order to identify novel treatment methods (8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑103 modulates tumor progression by targeting KLF7 in non‑small cell lung cancer

Yuan

2020

Int J Mol Med

View full text Add to dashboard Cite

Numerous studies have identified that microRNAs (miRs) play a crucial role in the tumorigenesis of non-small cell lung cancer (NSCLC). However, to the best of our knowledge, the physiological function of miR-103 in NSCLC is not fully understood. Experiments in the present study revealed that miR-103 expression was increased in NSCLC cell lines. In addition, a series of methods, including MTT, colony formation, 5-ethynyl-2'-deoxyuridine, Transwell, wound healing, flow cytometric, reverse transcription-quantitative PCR and western blot assays, were performed, which revealed that overexpression of miR-103 enhanced cell growth, migration, invasion and epithelial-mesenchymal transition (EMT), and suppressed apoptosis of A549 and H1299 cells. Additionally, a dual-luciferase reporter assay indicated that miR-103 directly targets the 3'-untranslated region of Kruppel-like factor 7 (KLF7), and KLF7 expression was negatively regulated by miR-103 expression. Furthermore, the present findings demonstrated that miR-103 promoted EMT via regulating the Wnt/β-catenin signaling pathway in NSCLC. Collectively, the current results demonstrated that miR-103 serves a tumorigenesis role in NSCLC development by targeting KLF7, at least partly via the Wnt/β-catenin signaling pathway. Consequently, these findings indicated that miR-103/KLF7/Wnt/β-catenin may provide a novel insight into underlying biomarkers for improving the diagnosis and treatment of NSCLC.

show abstract

Lung Cancer development and mortality in interstitial lung disease with and without connective tissue diseases: a five-year Nationwide population-based study

Cited by 19 publications

References 39 publications

Cumulative Incidences of Lung Cancer in Various Interstitial Lung Diseases

Cumulative Incidences of Lung Cancer in Various Interstitial Lung Diseases

Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies

MicroRNA‑103 modulates tumor progression by targeting KLF7 in non‑small cell lung cancer

Contact Info

Product

Resources

About